Amlitelimab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Amlitelimab comprises 4 peer-reviewed publications across 4 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Dermatitis, Atopic, and Lung Diseases, Interstitial. Most recent publication: A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study., Dermatol Ther (Heidelb), 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
    Weidinger S, Blauvelt A, Papp KA, et al. · J Allergy Clin Immunol · 2025
    PubMed: PMID 39522654 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic
  2. A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.
    Reich A, Blauvelt A, Weidinger S, et al. · Dermatol Ther (Heidelb) · 2026
    PubMed: PMID 41359216 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic
  3. Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
    Khanna D, Evnin LB, Assassi S, et al. · J Scleroderma Relat Disord · 2026
    PubMed: PMID 39544897 · NCT06195072 (CONQUEST) · Lung Diseases, Interstitial
  4. Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
    Blauvelt A, Chovatiya R, Merola JF, et al. · J Eur Acad Dermatol Venereol · 2025
    PubMed: PMID 40704660 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic

Publications by year

2025–2026: 4 publications.

2025
2
2026
2

Publications by indication

Dermatitis, Atopic (3)

  • A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.
    Dermatol Ther (Heidelb) · 2026 · PMID 41359216 · NCT05131477
  • Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
    J Allergy Clin Immunol · 2025 · PMID 39522654 · NCT05131477
  • Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
    J Eur Acad Dermatol Venereol · 2025 · PMID 40704660 · NCT05131477

Lung Diseases, Interstitial (1)

  • Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
    J Scleroderma Relat Disord · 2026 · PMID 39544897 · NCT06195072

Publications by journal

  • J Allergy Clin Immunol1 paper
  • Dermatol Ther (Heidelb)1 paper
  • J Scleroderma Relat Disord1 paper
  • J Eur Acad Dermatol Venereol1 paper

All Amlitelimab publications (4)

2026 (2 papers)

  1. A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.
    Reich A, Blauvelt A, Weidinger S, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
    PubMed: PMID 41359216 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic
  2. Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
    Khanna D, Evnin LB, Assassi S, et al. · J Scleroderma Relat Disord · 2026 · Derived
    PubMed: PMID 39544897 · NCT06195072 (CONQUEST) · Lung Diseases, Interstitial

2025 (2 papers)

  1. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
    Weidinger S, Blauvelt A, Papp KA, et al. · J Allergy Clin Immunol · 2025 · Derived
    PubMed: PMID 39522654 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic
  2. Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
    Blauvelt A, Chovatiya R, Merola JF, et al. · J Eur Acad Dermatol Venereol · 2025 · Derived
    PubMed: PMID 40704660 · NCT05131477 (STREAM-AD) · Dermatitis, Atopic

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 12 May 2026 16:51:17 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).